Vise Technologies’s Axsome Therapeutics AXSM Stock Holding History

Vise Technologies’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$231K	Hold	1,266	–	–	﹤0.01%	1306
2025 Q4	$231K	Buy	+1,266	New	+$177K	﹤0.01%	1316

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vise Technologies's AXSM Position: Q1 2026 in Review

Vise Technologies held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 1,266 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Vise Technologies first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Vise Technologies held 1,266 shares of Axsome Therapeutics worth $231K as of Q1 2026.
Vise Technologies left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Vise Technologies's portfolio in Q1 2026, its #1306 holding.
Vise Technologies first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.